Tag: statements

   
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

Highlights

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. The Fund is a mutual fund within defendant James Alpha Funds Trust’s series of mutual funds (which does business as Easterly Funds Trust).

Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America.

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

STAMFORD, Ct, Aug. 04, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp (Nasdaq: HCMAU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today the closing of its previously announced initial public offering of 25,300,000 units, including 3,300,000 units issued pursuant to the full exercise by the underwriter of its over-allotment option. The units were sold at a price of $10.00 per unit. The Company’s units began trading on August 1, 2025 on the Nasdaq Global Market under the symbol “HCMAU”. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq Global Market under the ticker symbols “HCMA” and “HCMAW,” respectively.

Jim Fink Investing’s Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities.

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.